Video Experimental Relacionado
Updated: May 5, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.0K
La lenalidomida causa una degradación selectiva de IKZF1 e IKZF3 en las células del mieloma múltiple
Jan Krönke1, Namrata D Udeshi, Anupama Narla
1Brigham and Women's Hospital, Boston, MA 02115, USA.
Science (New York, N.Y.)
|December 3, 2013
Resumen
La lenalidomida degrada selectivamente los factores de transcripción linfoide IKZF1 e IKZF3 al alterar la actividad de la E3 ubiquitina ligasa. Este mecanismo explica su eficacia en el mieloma múltiple y otros cánceres de células B.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Biología Molecular Biología Molecular
- Oncología Oncología.
Sus antecedentes:
- La lenalidomida es un terapéutico eficaz para el mieloma múltiple y las neoplasias de células B.
- El mecanismo preciso de acción de la lenalidomida sigue siendo en gran medida desconocido.
- Comprender los objetivos moleculares de la lenalidomida es crucial para optimizar su uso clínico.
Objetivo del estudio:
- Para dilucidar el mecanismo molecular de acción de la lenalidomida.
- Para identificar las proteínas específicas diana de la lenalidomida.
- Investigar el papel de la degradación de las proteínas inducida por la lenalidomida en sus efectos terapéuticos.
Principales métodos:
- Se empleó proteómica cuantitativa para identificar los cambios en las proteínas inducidos por la lenalidomida.
- Se realizaron ensayos de ubiquitinación y degradación para confirmar el compromiso del objetivo.
- La manipulación genética de los factores de transcripción se utilizó para evaluar los mecanismos de resistencia.
Principales resultados:
- El tratamiento con lenalidomida condujo a la ubiquitinación selectiva y la degradación de los factores de transcripción linfoide IKZF1 e IKZF3.
- Estos factores de transcripción son esenciales para la supervivencia y la proliferación de las células del mieloma múltiple.
- Una mutación específica en IKZF3 confirió resistencia a la lenalidomida, rescatando la inhibición del crecimiento celular.
- El agotamiento de IKZF1 e IKZF3 también fue responsable de la producción de interleucina-2 inducida por lenalidomida en las células T.
Conclusiones:
- La lenalidomida funciona secuestrando el complejo de ubiquitina ligasa CRBN-CRL4 para degradar IKZF1 e IKZF3.
- Esta degradación proteica dirigida es un mecanismo clave que subyace a la eficacia de la lenalidomida en las malignidades hematológicas.
- Los hallazgos revelan una nueva estrategia terapéutica que implica la modulación de las ligasas de ubiquitina E3 para la degradación proteica dirigida.
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
01:10Drugs that Destabilize Microtubules
3.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:58Regulated Protein Degradation
6.6K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
6.6K
02:23Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
01:45Destabilization of Microtubules
2.9K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.9K